Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT03411161 Completed - Clinical trials for Metastatic Breast Cancer

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Start date: January 4, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety profile, the maximum tolerated dose (MTD) and the associated dose-limiting toxicities (DLTs) of S 81694 in combination with paclitaxel in metastatic breast cancer (mBC) patients, and to investigate the antitumour activity of the combination in metastatic triple negative breast cancer (mTNBC) patients.

NCT ID: NCT03411070 Completed - Clinical trials for Stage IIIC Breast Cancer AJCC v7

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer

Start date: April 7, 2019
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial will evaluate whether the SCOUT reflector can be used to tag abnormal lymph nodes in patients with breast cancer prior to chemotherapy for targeted removal at the time of surgery. The SCOUT localization system with the SAVI reflector is non-radioactive and completely internal so can be placed into an abnormal lymph node prior to chemotherapy treatment, which theoretically will allow easier identification and therefore more reliable targeting of the abnormal lymph node for surgical removal.

NCT ID: NCT03409198 Completed - Breast Cancer Clinical Trials

Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer

ICON
Start date: January 21, 2018
Phase: Phase 2
Study type: Interventional

Breast cancer is rarely curable after metastasis, and the therapeutic options are limited. Interestingly, the host immune response is strongly predictive for the effect of chemotherapy in subgroups of patients with breast cancer. The aim is to release the brake on the immune response by use of ipilimumab, which blocks CTLA-4 and may deplete regulatory T cells, combined with nivolumab (anti PD1). Importantly, it is possible that non-responders to nivolumab/ipilimumab (nivo/ipi) can be turned responders by use of immunogenic chemotherapy.

NCT ID: NCT03408769 Completed - Clinical trials for Metastatic Breast Carcinoma

Metastatic Breast Carcinoma and Women Sexual Quality of Life

SexoMBC
Start date: March 12, 2018
Phase:
Study type: Observational

Sexual health is one of the relevant parameters for assesing the quality of life. Improvement sexual and emotional function improves quality of life scores and depression or anxiety in curative phase. The purpose of the study is to assess the quality of sexual life of postmenopausal women with metastatic breast cancer in couples and to establish links with overall quality of life and the quality of the relationship.

NCT ID: NCT03408717 Active, not recruiting - Breast Cancer Clinical Trials

Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery

B-CAPP
Start date: January 3, 2018
Phase:
Study type: Observational

Pre-existing pain and severe postoperative pain are predictors of persistent pain after surgery, but a complete understanding on the development of persistent pain is still lacking. The study aims to identify clinically relevant and genetic risk factors for persistent postsurgical pain that can be reliably distinguished statistically.

NCT ID: NCT03408561 Withdrawn - Lymphoma Clinical Trials

Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer

Start date: November 8, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well social media listening works in improving clinical trial recruitment in patients with cancer. Social media listening and recruitment on Twitter may enhance enrollment for cancer-related clinical trials.

NCT ID: NCT03408353 Recruiting - Breast Carcinoma Clinical Trials

Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study

Start date: September 15, 2017
Phase:
Study type: Observational

This study collects mammogram images, blood samples, and clinical information from women undergoing routine screening mammograms. Creating a bank of blood samples and a database of clinical and risk information may be used in future research related to breast cancer, other cancers, and women's health.

NCT ID: NCT03407768 Active, not recruiting - Breast Cancer Clinical Trials

Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer

MyCHOICE
Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Although combination endocrine therapy has been associated with significant reduction in risk of recurrence in younger women with hormone receptor positive breast cancer, it has been associated with more adverse effects and decline in quality of life (QOL). Various behavioral and complementary interventions can be effective in reducing treatment-related side effects. The study aims to evaluate if individually-tailored behavioral and complementary interventions could improve treatment tolerance and adherence in women with early stage breast cancer. This benefit will be assessed primarily by change in QOL and secondarily by adherence to adjuvant endocrine treatment.

NCT ID: NCT03407716 Completed - Cancer Survivor Clinical Trials

Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors

Start date: March 1, 2019
Phase: Early Phase 1
Study type: Interventional

This randomized pilot trial studies how well North American ginseng extract AFX-2 (ginseng) works in decreasing cancer-related fatigue after treatment in cancer survivors. Ginseng may decrease fatigue in people who were treated for cancer.

NCT ID: NCT03405168 Completed - Clinical trials for Advanced Breast Cancer

Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

Start date: January 1, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II,single center,prospective, single arm clinical trial. The objective is to evaluate the efficacy and safety of routine therapy plus moxifloxacin in Advanced Breast Cancer whose evaluation is stable disease with a trend of progression.